This was a randomised trial in 155 patients with non-diabetic CKD comparing aliskiren ( 150 mg/day ) ( n = 52 ) versus losartan ( 100 mg/day ) ( n = 52 ) and the third group aliskiren ( 150 mg/day ) combined with losartan ( 100 mg/day ) ( n = 51 ) .